[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

September 2019 - April 2015

Decade

Year

Issue

October 2019, Vol 5, No. 10, Pages 1379-1513

Original Investigation

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

Abstract Full Text
open access has active quiz has audio
JAMA Oncol. 2019;5(10):1411-1420. doi:10.1001/jamaoncol.2019.2187

This secondary analysis of the phase 1 CA209-003 clinical trial assesses the 5-year survival and other related factors among patients with advanced melanoma, renal cell carcinoma, or non–small cell lung cancer receiving nivolumab.

Assessment of Deep Natural Language Processing in Ascertaining Oncologic Outcomes From Radiology Reports

Abstract Full Text
JAMA Oncol. 2019;5(10):1421-1429. doi:10.1001/jamaoncol.2019.1800

This cohort study examines the use of deep natural language processing in extraction of information on cancer outcomes from the medical records of patients with lung cancer.

Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2019;5(10):1431-1438. doi:10.1001/jamaoncol.2019.1588

This phase 2 randomized clinical trial assesses the safety and efficacy of durvalumab with and without tremelimumab for the treatment of patients with metastatic pancreatic ductal adenocarcinoma.

Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma

Abstract Full Text
JAMA Oncol. 2019;5(10):1440-1447. doi:10.1001/jamaoncol.2019.1558

This biomarker analyss of patients with adrenocortical carcinoma compares the molecular classification for prognostic assessment of adrenocortical carcinoma with other known prognostic factors.

Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non–Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2019;5(10):1448-1455. doi:10.1001/jamaoncol.2019.1847

This phase 2 multicenter randomized clinical trial including 88 patients compares progression-free survival, and secondarily overall survival, overall response rate, and adverse events, in patients with stage 4 EGFR-mutant non–small cell lung cancer treated with erlotinib plus bevacizumab vs erlotinib alone.

Association Between Anesthesia Exposure and Neurocognitive and Neuroimaging Outcomes in Long-term Survivors of Childhood Acute Lymphoblastic Leukemia

Abstract Full Text
JAMA Oncol. 2019;5(10):1456-1463. doi:10.1001/jamaoncol.2019.1094

This cohort study examines the neurocognitive and neuroimaging outcomes associated with multiple use of general anesthesia in survivors of childhood acute lymphoblastic leukemia.

Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non–Small Cell Lung Cancer: A Phase 1/2 Trial

Abstract Full Text
JAMA Oncol. 2019;5(10):1464-1472. doi:10.1001/jamaoncol.2019.2095

This phase 1/2 trial evaluates the toxic effects, maximally tolerated dose, and recommended phase 2 dose of the protease inhibitor nelfinavir administered concurrently with chemoradiotherapy for locally advanced non–small cell lung cancer, and estimates the objective response rate, local and distant failure rates, and overall and progression-free survival.

Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018

Abstract Full Text
online only
JAMA Oncol. 2019;5(10):e191870. doi:10.1001/jamaoncol.2019.1870

This database study assesses the frequency of race reporting and proportional race representation in trials that support FDA oncology drug approvals.

Self-reported Reasons and Patterns of Noninsurance Among Cancer Survivors Before and After Implementation of the Affordable Care Act, 2000-2017

Abstract Full Text
online only
JAMA Oncol. 2019;5(10):e191973. doi:10.1001/jamaoncol.2019.1973

This survey study analyzes NHIS data from nearly 18 000 patients with a cancer diagnosis before and after implementation of the Affordable Care Act (ACA) to evaluate patterns and patient-reported reasons for not having health insurance before and after the ACA.

Brief Report

Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer

Abstract Full Text
JAMA Oncol. 2019;5(10):1473-1478. doi:10.1001/jamaoncol.2019.1838

This validation study assesses the clinical validity of molecular relapse detection with circulating tumor DNA analysis in early-stage breast cancer.

Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non–Small Cell Lung Cancer

Abstract Full Text
JAMA Oncol. 2019;5(10):1481-1485. doi:10.1001/jamaoncol.2019.1747

This exploratory pooled analysis of 11 randomized clinical trials examines whether the lung immune prognostic index is associated with long-term outcomes of treatment with immune checkpoint inhibitors and targeted therapy for patients with metastatic non–small cell lung cancer.

Research Letter

Women’s Representation Among Lead Investigators of Clinical Trials in Oncology

Abstract Full Text
has audio
JAMA Oncol. 2019;5(10):1501-1502. doi:10.1001/jamaoncol.2019.2196

This database study assesses the number of female lead investigators of randomized clinical trials registered in ClinicalTrials.gov.

Association of Gender and Parenthood With Conference Attendance Among Early Career Oncologists

Abstract Full Text
JAMA Oncol. 2019;5(10):1503-1504. doi:10.1001/jamaoncol.2019.1864

This survey study evaluates the association of gender and parenthood status with conference attendance among career oncologists.

Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types

Abstract Full Text
open access
JAMA Oncol. 2019;5(10):1504-1506. doi:10.1001/jamaoncol.2019.2963

This cohort study analyzes the medical records of 47 721 patients with various cancer types with POLE/POLD1 mutations to evaluate whether the mutations were associated with immunotherapy outcomes.

Pathogenic Germline Variants in Patients With Metastatic Breast Cancer

Abstract Full Text
JAMA Oncol. 2019;5(10):1506-1508. doi:10.1001/jamaoncol.2019.3116

This genetic association study examines the prevalence of pathogenic/likely pathogenic germline variants among patients with metastatic breast cancer.

Review

Insights Into Breast Cancer in the East vs the West: A Review

Abstract Full Text
JAMA Oncol. 2019;5(10):1489-1496. doi:10.1001/jamaoncol.2019.0620

This review examines the differences in the epidemiology, tumor and host biology, and treatment of breast cancer in the East compared with the West.

JAMA Oncology Clinical Challenge

Weakness and Myalgia in a Patient With Hepatocellular Carcinoma Undergoing Checkpoint Inhibitor Therapy

Abstract Full Text
has active quiz
JAMA Oncol. 2019;5(10):1497-1498. doi:10.1001/jamaoncol.2019.2304

A man in his 50s with nonalcoholic steatohepatitis and hepatocellular carcinoma undergoing checkpoint inhibitor therapy experiences weakness and myalgia. What is your diagnosis?

Viewpoint

A Broad Impact for Global Oncology

Abstract Full Text
JAMA Oncol. 2019;5(10):1397-1398. doi:10.1001/jamaoncol.2019.2387

This Viewpoint examines the components and benefits of a systems approach to meeting the challenges of global oncology.

An Important Gap in Informed Consent Documents for Oncology Clinical Trials: Lack of Quantitative Details About Expected Treatment Outcomes

Abstract Full Text
JAMA Oncol. 2019;5(10):1399-1400. doi:10.1001/jamaoncol.2019.3146

This Viewpoint asuggests that a clear quantitative presentation of the assumptions and expectations used in the planning of clinical trials should be included in written consent forms.

Relieving Physical and Psychosocial Pain in Patients With Cancer—The Search for Enlightened Academic Medical Leaders

Abstract Full Text
JAMA Oncol. 2019;5(10):1401-1402. doi:10.1001/jamaoncol.2019.3353

This Viewpoint discusses the need for academic medical leaders to emphasize education and research on supportive and palliative care programs to address physical and psychosocial pain in patients with cancer.

Editorial

Appraising the Tail of the Survival Curve in the Era of PD-1/PD-L1 Checkpoint Blockade

Abstract Full Text
JAMA Oncol. 2019;5(10):1403-1405. doi:10.1001/jamaoncol.2019.2186
Invited Commentary

The Tipping Point for Deep Learning in Oncology

Abstract Full Text
JAMA Oncol. 2019;5(10):1429-1430. doi:10.1001/jamaoncol.2019.1799

Dual Checkpoint Inhibition in Pancreatic Cancer: Revealing the Limitations of Synergy and the Potential of Novel Combinations

Abstract Full Text
JAMA Oncol. 2019;5(10):1438-1439. doi:10.1001/jamaoncol.2019.1583

Circulating Tumor DNA as a Marker for Disease Relapse in Early-Stage Breast Cancer—Bad Blood

Abstract Full Text
JAMA Oncol. 2019;5(10):1479-1480. doi:10.1001/jamaoncol.2019.2047
Cancer Care Chronicles

Not on My Watch

Abstract Full Text
JAMA Oncol. 2019;5(10):1395-1396. doi:10.1001/jamaoncol.2019.1904

This article describes the experiences of a first-year oncology fellow’s experience as he treats his first patient.

Poetry and Oncology

Old Friend—HCT116

Abstract Full Text
JAMA Oncol. 2019;5(10):1513. doi:10.1001/jamaoncol.2019.2318
Comment & Response

Design of Noninferiority Trials for Hypofractionated vs Conventional Radiotherapy Among Patients With Cancer

Abstract Full Text
JAMA Oncol. 2019;5(10):1508-1509. doi:10.1001/jamaoncol.2019.2391

Whole Grains and Risk of Hepatocellular Carcinoma—Missing the Forest for the Trees?

Abstract Full Text
JAMA Oncol. 2019;5(10):1509. doi:10.1001/jamaoncol.2019.2968

Whole Grains and Risk of Hepatocellular Carcinoma—Missing the Forest for the Trees?—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(10):1509-1510. doi:10.1001/jamaoncol.2019.2988

The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer

Abstract Full Text
JAMA Oncol. 2019;5(10):1510-1511. doi:10.1001/jamaoncol.2019.2982

The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer

Abstract Full Text
JAMA Oncol. 2019;5(10):1511-1512. doi:10.1001/jamaoncol.2019.2985

The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(10):1512. doi:10.1001/jamaoncol.2019.2991
Correction

Error in Description of Treatment Safety Information

Abstract Full Text
free access
JAMA Oncol. 2019;5(10):1512-1513. doi:10.1001/jamaoncol.2019.3291

Error in Figure 2B Number at Risk Table

Abstract Full Text
free access
JAMA Oncol. 2019;5(10):1513. doi:10.1001/jamaoncol.2019.4168
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2019;5(10):1382. doi:10.1001/jamaoncol.2018.4786
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2019;5(10):1379. doi:10.1001/jamaoncol.2018.4785
×